Advanced searches left 3/3

Soft Tissue Sarcoma - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 20 June 2022

* If you want to update the article please login/register

A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas

Based on a phase III report that compared eribulin and dacarbazine in the treatment of liposarcoma and leiomyosarcoma, the FDA has approved eribulin and pesarcoma. Although the FDA hasn't approved pepolizumab for this particular disorder, other uses have been permitted. Rare responses of liposarcoma and undifferentiated pleomorphic sarcoma to pesoolizuma therapy were found in a phase II study. Although eribulin in combination with peomyosarcoma, or undifferentiated pleomorphic sarcoma have not been tested in the treatment of liposarcoma, leiomyosarcoma, or undifferentiated pleomorphic sarcoma, other research studies and laboratory findings indicate that the combination of these drugs may help to discourage cancer cells from expanding. Chemotherapy treatment with eribulin may improve immunotherapy's response to immunotherapy with pemozumab" may contribute to immunotherapy with pemotherapy.

Source link: https://clinicaltrials.gov/ct2/show/NCT03899805


A Phase 1B Study of Ribociclib in Combination With Doxorubicin in Advanced Soft Tissue Sarcomas

"In patients with advanced soft tissue sarcomas, it is necessary to determine the optimal phase 2 dose of ribociclib in combination with doxorubicin. " In patients with advanced soft tissue sarcomas, we can establish preliminary anti-tumor activity of ribociclib in combination with doxorubicin. Patients are given ribociclib orally daily on days 1-7, as well as doxorubicin hydrochloride intravenously on day 10. Patients with disease progression after six cycles are given ribociclib PO daily on days 1-21. Patients are followed up within 30 days and then every 12 weeks for 12 months after completion of study and then every 12 weeks for 12 weeks. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT03009201


A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma

"Total necrosis rate following preoperative treatment with talimogene laherpvec in combination with radiation in patients with localized soft tissue sarcoma includes a pre-planned interim safety study to assess post-surgical wound complications. " During neo-adjuvant therapy and post-surgical wound complications, it was difficult to determine the toxicity of talimogene laherparepvec in combination with radiation in localized soft tissue sarcomas. To determine the percentage of tumor necrosis in surgical tumors, it is necessary to determine the percentage of tumor necrosis. To determine if the combination of preoperative talimogene laherparepvec with radiation will raise the expression of PD-L1 in soft tissue sarcomas. In patients with soft tissue sarcomas, it was difficult to determine the effect of preoperative talimogene laherparec with radiation on the tumor infiltrating and circulating immune cells. OUTLINE: At weeks 1, 4, 6, and 8, patients receive talimogene laherparepvec intratumorally or via intralesional injection. Patients undergo radiation therapy on Monday-Friday of weeks 2-6," beginning 1 week after the start of talimogene laherparepvec.

Source link: https://clinicaltrials.gov/ct2/show/NCT02923778


A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)

In two separate patient cohorts, respectively to determine the safety and tolerability of navtemadlin in combination with standard-dose radiotherapy in soft tissue sarcoma. To determine the maximum tolerated dose/recommended phase II dose of AMG 232 in combination with radiotherapy, it is necessary to determine the maximum tolerated dose/recommended phase II dose of AMG 232 in combination with radiotherapy. To investigate the possibility of locating tumor genetic mutations in cell-free circulating tumor deoxyribonucleic acid, deoxyribonucleic acid is isolated from exosomes, and determine the concordance of these findings with those from NGS. Patients undergone tumor tissue analysis for p53 gene status and receive navtemadlin orally on day 2, days 2 and 4, or days 1-5 of weeks 1 to 5, with no symptoms of disease progression or unacceptable toxicity in the absence of disease progression or unacceptable toxicity. Patients with a wild-type p53 gene status are grouped in Group I, while patients with deleted/mutant p53 gene status are assigned to Group II. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT03217266


Phase I-II Prospective Trial, Multicenter, Open Label, Exploring the Combination of Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients

"In this report, researchers want to track tumor response when administering trabectedin a standard dose or inferior with simultaneous radiotherapy therapy. " A phase I trial will determine RECIST and Choi response, progression-free survival, overall survival, and quality of life information, with a phase I trial proving the appropriate dose level to conduct a phase II trial. Patients with locally advanced resectable soft tissue sarcoma and cohort B: Patients with peritoneal and resectable soft tissue sarcoma are among those enrolled in this trial. Unlimited cycles of chemotherapy are considered to be helpful to cohort A patients, although cohort B and C only 3 cycles are indicated. Patients on cohort A will be treated with 30Gy, while cohort B and C will receive 45Gy. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT02275286


A Biomarker Driven, Open Label, Phase II Study of VEGFR2 Inhibitor Apatinib in Patients With Recurrent or Refractory Advanced Bone and Soft Tissue Sarcoma

In up to 40% of cases, pulmonary metastases of bone and soft tissue sarcoma persist, and are also difficult without a good diet. Apatinib has been identified as a novel oral kinase inhibitor of receptor tyrosine targeting VEGFR2 as an angiogenesis inhibitor. Following multi-line chemotherapy failure, Apatinib, as well as other novel VEGFR inhibitors, showed promising anti-sarcoma activity with a 4 month progression free rate ranging from 40 to 60% in advanced bone and soft tissue sarcoma. The investigators intend to investigate the clinical signs of pneumothorax occurrence as well as the safety of Apatinib monotherapy for advanced bone and soft tissue sarcoma in association with VEGFR-2 604 genotype. In two cohorts, the observational study cohort and the prospective clinical trial cohort, we intend to continue our clinical research in two cohorts. We recruited patients with anti-angiogenic TKIs who experience pneumothorax during the course of the therapy as a global study in the population as a real world study. According to our sample size estimates, only VEGFR-2 604A > G polymorphism positive in biomarker-based selective patients will be evaluated during the primary endpoint of the trial.

Source link: https://clinicaltrials.gov/ct2/show/NCT04072042


A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer

"To find out whether the clinical benefit rate of gemcitabine and docetaxel has been enhanced by the metabolic changes triggered by ADI-PEG20, a phase II clinical trial of ADI with gemcitabine and docetaxel will be conducted" "Therefore, a phase II clinical trial of ADI with gemcitabine and docetaxel will be conducted. " As an exploratory cohort, an exploratory cohort of ten patients diagnosed with either osteosarcoma or Ewing's sarcoma will be included as an exploratory cohort, and five patients with small cell lung cancer will be included. Enrollment to Cohort 2 will take place simultaneously with Cohort 1. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT03449901


A Phase 2 Trial of Ixazomib for Kaposi Sarcoma

"Determine the overall response rate of ixazomib in participants of Kaposi sarcoma. " Assess changes in the Kaposi-sarcoma-associated herpesvirus viral load by ixazomib. With tumor responses, correlating changes in KSHV VL. For human immunodeficiency virus (HCV) positive participants, monitor changes in CD4 counts and HIV viral load. Patients are primarily affected by ixazomib on days 1, 8, and 15. Patients with complete or partial response can continue therapy for an additional 12 cycles in the absence of disease progression or unacceptable toxicity," says the author.

Source link: https://clinicaltrials.gov/ct2/show/NCT04305691

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions